Perrigo has announced it has received final approval for its abbreviated new drug application (ANDA) for Repaglinide, the generic version of Novo Nordisk’s Prandin.

RELATED: Endocrine Disorders Resource Center

Repaglinide is an oral meglitinide used in the management of non-insulin dependent type 2 diabetes mellitus. Repaglinide reduces blood glucose levels by stimulating the release of insulin from the pancreas and closing ATP-dependent potassium channels in the ß-cell membrane through binding at characterizable sites. As the potassium channel blockade depolarizes the ß-cell, the calcium channels are opened and the increased calcium induces insulin secretion.

Perrigo’s Repaglinide Tablets are available in 0.5mg, 1mg, and 2mg strengths.

For more information call (866) 634-9120 or visit Perrigo.com.